In conversation with
Benjamin Rovinski, PhD
Managing Director, Lumira Capital
John Holyoake, DPhil
Vice-President (Investment Banking), Bloom Burton
Investment Banker, D&D Securities Inc
Join the Science to Business Network with special guests Dr. Benjamin Rovinski (Lumira Capital), Dr. John Holyoake (Bloom Burton) and Tony Pullen (D&D Securities) who’ll be sharing their perspectives on Canada’s life sciences sector, the challenges in commercializing research, and how Canada and those who work in and around the healthcare and life sciences sectors need adapt to stay competitive.
Benjamin Rovinski's biography:
Dr. Benjamin Rovinski has 27 years of investment, operational, managerial and research experience in the healthcare sector. Beni joined Lumira Capital in 2001, where he is a Managing Director, with an investment focus on mid-to late-stage private and public life sciences companies. With a proven track record of delivering results both as a senior scientist and a business executive, Beni has held several senior management positions in the biotechnology sector, including 13 years at Sanofi Pasteur where he was a senior scientist and director of molecular virology, with a particular focus in the areas of virology, vaccine development, recombinant protein production, and functional genomics. Beni led global research and development programs in the areas of HIV/AIDS and therapeutic cancer vaccines, bringing several of them through to clinical stage.
Beni received a PhD in biochemistry from McGill University and did post-doctoral studies in molecular oncology and retrovirology at the Ontario Cancer Institute in Toronto. He obtained his undergraduate degree from Rice University in Houston. Beni’s current and past board roles and investment responsibilities include several private and public companies. He also serves on the board of directors of Life Sciences Ontario and the steering committee of the Toronto Regional Board of Trade’s Health Science Cluster initiative. He has published over 25 scientific articles and reviews and is the recipient of 31 issued patents.
John Holyoake's Biography:
John Holyoake is Vice-President, Investment Banking, having joined Bloom Burton & Co. in January 2012. At Bloom Burton, John’s responsibilities include M&A advisory and monetization planning, as well as conducting technical and commercial due diligence of companies across all healthcare sectors. John’s area of expertise spans early-stage technologies to profitable healthcare service companies, with a particular focus on preclinical-stage biotech and the US healthcare system.
John joined Bloom Burton from a background of industry experience in the clinical stage oncology company TenX BioPharma and at the life science consulting group SHI Link, as well as being involved with several early-stage life science companies.John holds a Master’s in Biochemistry from the University of Oxford, received a doctorate from the same institution and made the transition across the Atlantic for a post-doctoral research fellowship at The Hospital for Sick Children, Toronto.
Tony Pullen's Biography:
Tony Pullen is one of the deans of Canadian capital markets. His career in biotech traces its roots to 1985 as an advisor to Cangene, which merged with Emergent BioSolutions (NYSE:EBS) in February. He also was instrumental in raising the initial capital for MDS Health Ventures, which went on to become MDS Capital Corp., formerly a leading biotech venture capital firm. In 1991, Mr. Pullen played a leading role in the formation of the biotech technology boutique within Yorkton Securities, which dominated a surge in sector financing until the early 2000s. After a restructuring of Yorkton, Mr. Pullen joined Paradigm Capital as a biotech investment banker and then subsequently left to work on his own with 15 to 20 relationship clients. He continues to work with his clients under the umbrella of D&D Securities.